Apollomics is registering up to 279,775 Class A ordinary shares for resale by selling securityholders under the prospectus. The shares represent approximately 9.6% of outstanding Class A stock, and Apollomics will receive no proceeds, while the prospectus warns sales could depress its shares and warrants.
Key Highlights
- The shares were issued under subscription agreements dated September 2, 2025.
- Apollomics is registering up to 279,775 Class A ordinary shares for resale by selling securityholders.
- The shares have a Par Value of $0.01 per share, and Apollomics will not receive proceeds from the resale transactions.
- The resale registration covers 9.6% of Apollomics’ Class A stock and could impair its ability to raise Capital through additional Equity securities.
Apollomics Inc. (NASDAQ: APLM) is registering up to 279,775 Class A ordinary shares for resale by selling securityholders. The registration covers shares issued under subscription agreements and gives those holders the ability to sell all or part of their holdings through the prospectus.
279,775 Class A Shares Registered
The securities are Class A ordinary shares with a par value of $0.01 per share. The selling securityholders will conduct sales for their own accounts, while Apollomics will cover the registration-related costs, expenses and fees. The holders will bear incremental selling expenses such as commissions and brokerage fees. Apollomics will not receive proceeds from those transactions. The company currently has only Class A ordinary shares outstanding.
It also says those sales could impair Apollomics’ ability to raise capital through additional equity securities. Apollomics states that it cannot predict the effect of such sales on prevailing prices.
FAQs
Q: How many Apollomics shares are covered by the secondary offering?
A: The Apollomics secondary offering covers up to 279,775 Class A ordinary shares. The shares may be sold from time to time by the named selling securityholders.
Q: Will Apollomics receive money from the share resale?
A: No, Apollomics will not receive proceeds from the share resale. The selling securityholders will conduct sales for their own accounts, while the holders bear incremental selling expenses such as commissions and brokerage fees.
Q: What is the investor risk from the Apollomics resale registration?
A: The prospectus says sales, or expectations of sales, could depress Apollomics’ Class A ordinary shares and warrants. It also identifies a possible effect on future equity fundraising.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.